



## Arbutus to Participate in Upcoming Investor Conferences

May 26, 2021

WARMINSTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following upcoming investor conferences:

### Jefferies Virtual Healthcare Conference

- Wednesday, June 2, 2021 at 9:00 am ET (Fireside Chat)
- Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer
- [Webcast Link](#)

### JMP Securities Life Sciences Conference - Virtual

- Thursday, June 17, 2021 at 11:00 am ET (Fireside Chat)
- Presenters: William Collier; Dr. Michael Sofia; Dr. Gaston Picchio; and David Hastings
- [Webcast Link](#)

The webcast links for the virtual fireside chats can also be accessed through the Investors section of Arbutus' website at [www.arbutusbio.com](http://www.arbutusbio.com). An archived replay of the webcast will be available on the Company's website after the conference.

### About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### Contact Information

#### **Investors and Media**

William H. Collier  
President and CEO  
Phone: 267-469-0914  
Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)

Pam Murphy  
Investor Relations Consultant  
Phone: 267-469-0914  
Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)